Short Interest in SciSparc Ltd. (NASDAQ:SPRC) Increases By 691.3%

SciSparc Ltd. (NASDAQ:SPRC) was the target of a large increase in short interest in September. As of September 15th, there was short interest totalling 273,800 shares, an increase of 691.3% from the August 31st total of 34,600 shares. Based on an average daily trading volume, of 3,610,000 shares, the short-interest ratio is currently 0.1 days. Approximately 11.2% of the company’s stock are sold short.

SciSparc Trading Down 2.0 %

Shares of SciSparc stock traded down $0.01 during trading hours on Wednesday, hitting $0.25. The company had a trading volume of 261,813 shares, compared to its average volume of 1,761,522. The company’s 50-day moving average is $0.39 and its two-hundred day moving average is $1.00. SciSparc has a twelve month low of $0.24 and a twelve month high of $14.22.

Institutional Trading of SciSparc

A hedge fund recently bought a new stake in SciSparc stock. Renaissance Technologies LLC purchased a new stake in SciSparc Ltd. (NASDAQ:SPRC) in the second quarter, according to the company in its most recent filing with the SEC. The firm purchased 39,700 shares of the company’s stock, valued at approximately $32,000. Renaissance Technologies LLC owned approximately 5.59% of SciSparc as of its most recent SEC filing. 25.06% of the stock is owned by institutional investors.

SciSparc Company Profile

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution.